Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Meike E. W. Logtenberg(The Netherlands Cancer Institute), J.H. Marco Jansen(University Medical Center Utrecht), Matthijs Raaben(The Netherlands Cancer Institute), Mireille Toebes(The Netherlands Cancer Institute), Katka Franke(Sanquin), Arianne M. Brandsma(University Medical Center Utrecht), Hanke L. Matlung(Sanquin), Astrid Fauster(The Netherlands Cancer Institute), Raquel Gomez-Eerland(The Netherlands Cancer Institute), Noor A. M. Bakker(The Netherlands Cancer Institute), Simone van der Schot(The Netherlands Cancer Institute), Koen A. Marijt(Leiden University Medical Center), Martijn Verdoes(Radboud University Nijmegen), John B.A.G. Haanen(The Netherlands Cancer Institute), Joost H. van den Berg(The Netherlands Cancer Institute), Jacques Neefjes(Leiden University Medical Center), Timo K. van den Berg(Sanquin), Thijn R. Brummelkamp(The Netherlands Cancer Institute), Jeanette H.W. Leusen(University Medical Center Utrecht), Ferenc A. Scheeren(Leiden University Medical Center), Ton N. Schumacher(The Netherlands Cancer Institute)
Nature Medicine
March 4, 2019
Cited by 240Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis